The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies

Clicks: 284
ID: 267862
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Short-term levosimendan therapy of heart failure showed no tendency to increase cardiac arrhythmias. Although assessing only surrogates of prognostically significant arrhythmias, the findings together with previously observed reduction of mortality in heart failure therapy studies support the presum …
Reference Key
j2004scandinavianthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lilleberg J;Ylönen V;Lehtonen L;Toivonen L;;
Journal Scandinavian cardiovascular journal : SCJ
Year 2004
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/15204232
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't female male aged middle aged Drug Administration Schedule Comparative Study randomized controlled trials as topic follow-up studies dose-response relationship drug risk assessment probability intravenous finland electrocardiography* infusions registries clinical trials phase iii as topic arrhythmias pmid:15204232 doi:10.1080/14017430410025783 jyrki lilleberg vesa ylönen lauri toivonen anti-arrhythmia agents / administration & dosage* anti-arrhythmia agents / adverse effects cardiac / complications cardiac / diagnosis cardiac / drug therapy* heart failure / complications heart failure / diagnosis heart failure / drug therapy* hydrazones / administration & dosage* hydrazones / adverse effects myocardial contraction / drug effects pyridazines / administration & dosage* pyridazines / adverse effects simendan

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.